Picture loading failed.

Anti-CD40 therapeutic antibody (Pre-made Ravagalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ravagalimab (formerly ABBV 323), a CD40 antagonist biologic, is being developed by AbbVie, for the treatment of ulcerative colitis and Sjogren's syndrome.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-471-1mg 1mg 3090
GMP-Bios-ab-471-10mg 10mg 21890
GMP-Bios-ab-471-100mg 100mg 148000
GMP-Bios-ab-471-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD40 therapeutic antibody (Pre-made Ravagalimab biosimilar,Whole mAb)
INN Name Ravagalimab
TargetCD40
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI Structure6pe7:HL/6pe8:HL:AB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesAbbVie
Conditions Approvedna
Conditions ActiveUlcerative colitis;Sjogren's syndrome
Conditions DiscontinuedCrohn's disease
Development Techna